Why does quick-release bromocriptine decrease cardiac events?

Diabetes, Obesity and Metabolism

Volumn 13, Issue 10, 2011, Pages 880-884

  Bell, David S H ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cardiovascular disease; Diabetes complications; Type 2 diabetes

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROMOCRIPTINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIURETIC AGENT; DOPAMINE 2 RECEPTOR; FATTY ACID; GLITAZONE DERIVATIVE; GLUCOSE; INCRETIN; INSULIN; NATEGLINIDE; PLACEBO; PRAMLINTIDE; TRIACYLGLYCEROL; VALSARTAN;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROMA; BLOOD PRESSURE; CIRCADIAN RHYTHM; CLINICAL TRIAL (TOPIC); CONTROLLED DRUG RELEASE; DISEASE COURSE; DRUG MECHANISM; DRUG SAFETY; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; HEART DISEASE; HEART FAILURE; HEART RATE; HUMAN; HYPERGLYCEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LEAN BODY WEIGHT; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SYMPATHETIC TONE;

EID: 80052543510     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01424.x     Document Type: Review

References (50)

1. Gaziano JM, Cincotta AH, O'Connor CM et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 2010; 33: 1503-1508.
2. Holt RI, Barnett AH, Bailie CJ. Bromocriptine: old drug, new formulation and new indication. Diab Obes Metab 2010; 12: 1048-1057.
3. DeFronza RA. Bromocriptine: a sympatholytic d2 - dopamine agonist for the treatment of type 2 diabetes. Diabetes Care 2011; 34: 789-794.
4. La Fleur, SE. Daily rhythms in glucose metabolism: suprachiasmatic nucleus output to peripheral tissue. J Neuroendocrinol 2003; 15: 315-322.
5. Lee A, Ader M, Bray GA, Bergman RN. Diurnal variation in glucose tolerance. Cyclic suppression of insulin action and insulin secretion in normal-weight, but not obese, subjects. Diabetes 1992; 41: 750-759.
6. Boden G, Ruiz J, Urbain JL, Chen X. Evidence for a circadian rhythm of insulin secretion. Am J Physiol 1996; 271(2 Pt 1): E246-E252.
7. Boden G, Chen X, Polansky M. Disruption of circadian insulin secretion is associated with reduced glucose uptake in first-degree relatives of patients with type 2 diabetes. Diabetes 1999; 48: 2182-2188.
8. Boden G, Chen X, Urbain JL. Evidence for a circadian rhythm of insulin sensitivity in patients with NIDDM caused by cyclic changes in hepatic glucose production. Diabetes 1996; 45: 1044-1050.
9. Lam TK, Pocai A, Gutierrez-Juarez R et al. Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis. Nat Med 2005; 11: 320-327.
10. Obici S, Feng Z, Karkanias G, Baskin DG, Rossetti L. Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. Nat Neurosci 2002; 5: 566-572.
11. Obici S, Feng Z, Arduini A, Conti R, Rossetti L. Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production. Nat Med 2003; 9: 756-761.
12. Lam CK, Chari M, Lam TK. CNS regulation of glucose homeostasis. Physiology (Bethesda) 2009; 24: 159-170.
13. Luo S, Luo J, Cincotta AH. Chronic ventromedial hypothalamic infusion of norepenephrine and serotonin promotes insulin resistance and glucose intolerance. Neuroendocrinology 1999; 70: 460-465.
14. Cincotta AH, Meier AH, Cincotta Jr M. Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs 1999; 8: 1683-1707.
15. Luo S, Meier AH, Concotta AH. Bromocriptine reduces obesity, glucose intolerance and extra-cellular monoamine metabolite levels in the ventro-medial hypothalamus of Syrian hamsters. Neruoendocrinology 1998; 68: 1-10.
16. Cincotta AH, Meier AH. Bromocriptine and lean body mass. Diabetes Care 1999; 19: 667-670.
17. Dotson S, Freeman R, Failing HJ, Adler GK. Hypoglycemia increases serum interleukin-6 levels in healthy men and women. Diabetes Care 2008; 31: 1222-1223.
18. Marques JL, George E, Peacey SR et al. Altered ventricular repolarization during hypoglycaemia in patients with diabetes. Diabet Med 1997; 14: 648-654.
19. Falk RH, Desilva RD, Lown B. Reduction in vulnerability to ventricular fibrillation by bromocriptine, a dopamine agonist. Cardiovasc Res 1981; 15: 175-180.
20. Van Loon GR, Sole MJ, Bain J, Ruse JL. Effects of bromocriptine on plasma catecholamines in normal men. Neuroendocrinology 1979; 28: 425-434.
21. Mannelli M, Delitala G, De Feo ML et al. Effects of different dopaminergic antagonists on bromocriptine-induced inhibition of norepinephrine release. J Clin Endocrinol Metab 1984; 59: 74-78.
22. Catania RA, Sowers JR, Stern N, Tuck ML, Paris J. Altered dopaminergic modulation of sympathetic nervous system activity in idiopathic edema. J Endocrinol Invest 1984; 7: 461-466.
23. Mohanty PK, Sowers JR, Beck FW et al. Catecholamine, renin, aldosterone, and arginine vasopressin responses to lower body negative pressure and tilt in normal humans: effects of bromocriptine. J Cardiovasc Pharmacol 1985; 7: 1040-1047.
24. Luo S, Liang Y, Cincotta AH. Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose intolerant state in hamsters. Neruoendocrinology 1999; 69: 160-166.
25. Schobel HP, Schmieder RE, Hartmann S, Schächinger H, Luft FC. Effects of bromocriptine on cardiovascular regulation in healthy humans. Hypertension 1995; 25: 1075-1082.
26. Przuntek H Przuntek H, Welzel D et al. Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued. Eur J Clin Pharmacol 1992; 43: 357-363.
27. Meredith IT, Broughton A, Jennings GL, Esler MD. Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N Engl J Med 1991; 325: 618-624.
28. Bell DS. Treatment of diabetic hypertension. Diab Obes Metab 2009; 11: 433-444.
29. Huggett RJ, Scott EM, Gilbey SG, Stoker JB, Mackintosh AF, Mary DA. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 2003; 108: 3097-3101.
30. Nielsen FS, Hansen HP, Jacobsen P et al. Increased sympathetic activity during sleep and nocturnal hypertension in Type 2 diabetic patients with diabetic nephropathy. Diab Med 1999; 16: 555-562.
31. Francis GS, Parks R, Cohn JN. The effects of bromocriptine in patients with congestive heart failure. Am Heart J 1983; 106(1 Pt 1):100-106.
32. Goldberg LI. The role of dopamine receptors in the treatment of congestive heart failure. J Cardiovasc Pharmacol 1989; 5(Suppl. 14): S19-27.
33. Mejía-Rodríguez O, Alvarez-Aguilar C, Vega-Gómez HE, Belio-Caro F, Vargas-Espinosa JM, Paniagua-Sierra JR. Bromocriptine induces regression of left ventricular hypertrophy in peritoneal dialysis patients. Proc West Pharmacol Soc 2005; 48: 122-125.
34. Sliwa K, Blauwet L, Tibazarwa K et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation 2010; 121: 1456-1473.
35. Alexander RW, Gill JR Jr, Yamabe H, Lovenberg W, Keiser HR. Effects of dietary sodium and of acute saline infusion on the interrelationship between dopamine excretion and adrenergic activity in man. J Clin Invest 1974; 54: 194-200.
36. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996; 78: 902-907.
37. Zannad F, McMurray JJ, Krum H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21.
38. Bell DS. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 2003; 26: 2433-2441.
39. Copinschi G, De Laet MH, Brion JP et al. Simultaneous study of cortisol, growth hormone and prolactin nyctohemeral variations in normal and obese subjects. Influence of prolonged fasting in obesity. Clin Endocrinol (Oxf) 1978; 9: 15-26.
40. Luo S, Luo J, Cincotta AH. Association of the antidiabetic effects of bromocriptine with a shift in the daily rhythm of monoamine metabolism within the suprachiasmatic nuclei of the Syrian hamster. Chronobiol Int 2000; 17: 155-172.
41. Bell DS. Diabetes: a cardiac condition manifesting as hyperglycemia. Endocr Pract 2008; 14: 924-932.
42. O'Keefe JH, Bell DS. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol 2007; 100: 899-904.
43. Bell DS, Bell DSH, O'Keefe JH, Jellinger P. Postprandial dysmetabolism: the missing link between diabetes and cardiovascular events? Endocr Pract 2008; 14: 112-124.
44. Ceriello A, Piconi L, Quagliaro L et al. Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes. Diabetes Care 2005; 28: 632-637.
45. Mellen PB, Bittner V, Herrington DM. Post-challenge glucose predicts coronary atherosclerotic progression in non-diabetic, post-menopausal women. Diab Med 2007; 24: 1156-1159.
46. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486-494.
47. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004; 25: 10-16.
48. Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004; 35: 1073-1078.
49. NAVIGATOR Study Group, Holman RR, Haffner SM, McMurray JJ et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 1463-1476.
50. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298: 1216-1218.